Invention Grant
- Patent Title: Single layer oral dose of neuro-attenuating ketamine
-
Application No.: US15885231Application Date: 2018-01-31
-
Publication No.: US10653629B2Publication Date: 2020-05-19
- Inventor: Alex Nivorozhkin , Nelson Landrau
- Applicant: Amorsa Therapeutics, Inc.
- Applicant Address: US MA Littleton
- Assignee: Amorsa Therapeutics, Inc.
- Current Assignee: Amorsa Therapeutics, Inc.
- Current Assignee Address: US MA Littleton
- Agency: Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
- Agent Peter Corless
- Main IPC: A61K9/20
- IPC: A61K9/20 ; A61K31/135 ; A61K31/13

Abstract:
The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.
Public/Granted literature
- US20180153813A1 SINGLE-LAYER ORAL DOSE OF NEURO-ATTENUATING KETAMINE Public/Granted day:2018-06-07
Information query